Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals, Inc. have initiated a randomized, double-blind, placebo-controlled Phase III trial studying Nexavar tablets administered in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). The multicenter study will compare Nexavar when co-administered with two chemotherapeutic agents—carboplatin and paclitaxel—versus carboplatin and paclitaxel alone. The study is expected to en...